Menu
Innovation Observatory > Reports > Drugs > Pembrolizumab (KEYTRUDA®) for advanced, metastatic oesophageal cancer – second line

< Back

Pembrolizumab (KEYTRUDA®) for advanced, metastatic oesophageal cancer – second line

Drugs

Cancer and Palliative Care

September 2017


The most common treatment options for oesophageal cancer in the UK is surgery; alternative treatments are radiotherapy and chemotherapy. Pembrolizumab is a type of immunotherapy, which works targeting specific proteins that stimulates an immune response that targets the cancer cells. It increases the body’s natural ability to identify and attack cancer cells. If licenced, pembrolizumab will offer an additional treatment option for patients with oesophageal cancer and prolong the time without cancer progression.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information



Load More Related Posts
Get Alerts